NCT02036424View on ClinicalTrials.gov

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ozurdex

intravitreal steroid

DRUG

Bevacizumab

antiVEGF

Trial Locations (1)

46290

Raj K Maturi MD PC, Indianapolis

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Raj K. Maturi, MD

INDIV